Latest news with #MultiomicsAdvancedTechnology™
Yahoo
22-05-2025
- Business
- Yahoo
GATC Health Paper Quantifies AI-Driven Capital Efficiencies and Advances Human-Centered Drug Discovery
IRVINE, Calif., May 22, 2025 /PRNewswire/ -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine. The paper details how advancements such as GATC's Multiomics Advanced Technology™ (MAT) platform are reshaping pharmaceutical development by improving speed, cost, and accuracy while reducing reliance on animal testing through human-relevant AI models. Ultimately, these technologies provide practical solutions to the industry's key challenges and promise to deliver better, safer treatments—faster—to patients. Highlights include: Validated, Highly Accurate Predictions: GATC Health's MAT was validated by University of California, Irvine, with predictions of sensitivity at 86% and specificity at 91%. Digital Twin Models: Models of human biological systems can test thousands of drug candidates in silico—achieving results 1,000x faster than conventional methods and at dramatically lower cost. Reduction in Animal Testing: The platform simulates human biology, enabling accurate predictions without animal studies and supporting regulatory shifts like the FDA Modernization Act. AI-driven methods could replace animal testing for up to 38.4 million animals annually. Public Health Impact: Accelerated drug development means faster access to new therapeutics, with the potential to save millions of years of human life. "This paper underscores our commitment to scientific and ethical progress in drug discovery," said Jayson Uffens, Chief Technology Officer at GATC Health. "By improving capital efficiency and reducing animal testing, we aim to advance both innovation and responsibility in the industry." Transforming Drug Development EconomicsTraditional drug development can cost up to $2.4 billion and take 12 years per drug. GATC's MAT platform streamlines discovery and preclinical phases, enabling companies to avoid costly investments in unlikely candidates and reinvest savings into further research. As noted in the paper, AI-driven preclinical assessments can cut animal use, increase human relevance, and reduce expenses by up to 90%. This streamlined process can shorten time to Investigational New Drug (IND) filing from over a decade to under two years. Advancing Ethical, Cost-Effective SolutionsConventional animal models often fail to predict human outcomes and raise ethical issues. GATC's AI-driven approach reduces animal use by up to 70% per drug candidate, aligning with global moves toward non-animal testing. Virtual toxicology datasets and digital twins replace animal models with more accurate and humane alternatives. Aligning with Regulatory TrendsThe paper details how AI technologies support evolving regulatory requirements, enabling faster, more precise, and ethically responsible drug development. GATC Health invites industry stakeholders to review the full paper and participate in the ongoing dialogue about the future of drug discovery. Visit GATC Health's Resources page to download the full paper. About GATC HealthGATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry's billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and derisk drug pipelines by predicting efficacy, safety, and off-target more information, visit View original content to download multimedia: SOURCE GATC Health Corp
Yahoo
28-01-2025
- Business
- Yahoo
West Virginia University and GATC Health Partner to Launch Strategic Program to Accelerate Academic Research into Market-Ready Therapies
The innovative program harnesses GATC's AI-powered platform to rapidly de-risk and optimize drug discovery and development, accelerating the transition to clinical trials. MORGANTOWN, Jan. 28, 2025 /PRNewswire/ -- West Virginia University (WVU), one of the top public research institutions in the nation, has formed a strategic partnership with GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery. The collaborative agreement facilitates the combination of WVU's early-stage drug research and GATC's AI drug discovery platform to accelerate commercialization and create de-risked bio-tech investment opportunities. The program aims to de-risk and accelerate the commercialization of groundbreaking research conducted at WVU. Utilizing GATC Health's Multiomics Advanced Technology™ (MAT) AI, which simulates complex systems biology with approximately 90% accuracy, the program empowers researchers to simulate billions of biological interactions, enabling rapid, accurate target discovery, drug identification, and testing at the earliest stages of drug development. By predicting safety, efficacy, and off-target effects, GATC's platform reduces the risk, time, and cost of traditional drug discovery while simulating clinical trial outcomes before laboratory work begins. GATC's technology has contributed to significant discoveries in addiction, PTSD, diabetes, obesity, glioblastoma, and cognitive decline. The partnership not only advances academic research but also creates compelling investment opportunities by significantly reducing the risks traditionally associated with biopharma ventures. By leveraging GATC Health's AI, the program identifies high-potential projects early in the drug development process. This precision enables faster decision-making while de-risking university research as it progresses toward pre-clinical work, IND-enabling studies, and clinical trials. As the exclusive AI partner with Lloyd's of London syndicate Medical & Commercial International and in partnership with Acrisure Re Corporate Advisory & Solutions, the international financing and consulting firm responsible for program sales and distribution, GATC is supporting the underwriting of the first insurance-backed financial program to fund clinical trials, offering a secure and innovative funding source for joint ventures stemming from WVU and GATC collaborations. "This partnership highlights West Virginia University's dedication to driving innovation and transforming lives through groundbreaking research," said Dr. Clay Marsh, Chancellor & Executive Dean for Health Sciences at West Virginia University. "By joining forces with GATC Health and utilizing their cutting-edge AI technology, we are empowering our researchers to accelerate the path from academic discovery to life-changing therapies, ensuring WVU remains at the forefront of addressing critical healthcare challenges and delivering meaningful outcomes that benefit patients in West Virginia and across the globe." Traditional drug discovery and development is a notoriously risky, expensive, and time-consuming process, often requiring over a decade and billions of dollars to bring a single therapy to market. The high failure rate—nearly 90% of drug candidates fail during clinical trials—stems from challenges such as inaccurate target identification, unforeseen toxicity, poor efficacy, and lengthy preclinical and clinical trial processes. By applying GATC Health's AI across these critical stages, drug discovery is becoming faster, more efficient, and more likely to succeed. "We are thrilled to partner with WVU and launch our University Research Accelerator Program," said Tyrone Lam, Chief Business Officer of GATC Health Corp. "This collaboration highlights our commitment to empowering academic institutions with cutting-edge AI tools that bridge the gap between research and commercialization, enabling faster delivery of life-changing therapies." By focusing on high-probability projects and leveraging GATC's "fast-fail" AI analysis, WVU will not only enhance its research capacity but also generate revenue much earlier in the discovery process. This innovative approach establishes WVU as a leader in AI-driven research commercialization. GATC West Virginia, a subsidiary of GATC Health, is enhancing its AI-powered lab operations within the WVU Innovation Building, strategically located near West Virginia University's campus. The state-of-the-art lab facilitates rapid iteration between GATC's MAT AI and traditional lab experiments. Currently, it is focused on synthesizing drug compounds, a critical step in advancing preclinical testing for innovative treatments targeting conditions such as opioid use disorder, polysubstance use disorder, post-traumatic stress disorder, anxiety, diabetes, glioblastoma, Alzheimer's and more. To support this growth, GATC West Virginia is expanding its preclinical capabilities by hiring additional scientists this year, reinforcing its commitment to innovation and scientific excellence. About West Virginia UniversityWest Virginia University, located in Morgantown, WV, is a leading public research institution dedicated to creating solutions that address the challenges of today and tomorrow. Through its world-class faculty and innovative research initiatives, WVU is driving advancements across a wide range of disciplines. About GATC Health CorpGATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry's billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects. For more information, visit View original content to download multimedia: SOURCE GATC Health Corp
